基本信息
浏览量:455
职业迁徙
个人简介
Sumanta (Monty) Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.
Dr. Pal entered college at the age of 13 and began medical school at University of California Los Angeles at the age of 17. After completing his residency training at UCLA, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he has remained on faculty since 2009.
Over that span of time, he has published more than 300 PubMed cited articles that have been featured in prominent journals including Cancer Discovery, The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell and European Urology.
Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the West Coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at the Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets. He is the lead investigator on multiple trials, ranging from early phase 1 experiences to late stage phase 3 studies.
Dr. Pal sits on the editorial board for Kidney Cancer and is a reviewer for multiple journals including Lancet Oncology, The Journal of Clinical Oncology, The Journal of Urology, European Urology and many others. Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network and multiple other leading entities in support of his formidable research.
Clinical Teams
Bladder Cancer
Kidney and Renal Cancer
Medical Oncology & Therapeutics Research
Prostate Cancer
Testicular Cancer
Urology and Urologic Cancers Program
Awards
2020, 40 Under 40 in Cancer
2020, Los Angeles Business Journal, Top Doctor
Memberships
2006-present, American Society of Clinical Oncology
2017-present, Cancer Communications Committee, Chair
2016-present, Leadership Development Program
2015-present, Social Media Working Group
2013-present, Genitourinary Cancers Committee
2012-2013, HER2-Positive Breast Cancer Committee
2010-present, National Comprehensive Cancer Network Bladder Cancer Committee
2015-present, Kidney Cancer Association Scientific Program Committee, Chair
2015-present, Society of Immunotherapy for Cancer Patient Meeting, Chair
2015-present, Society of Urologic Oncology Prostate Cancer Committee, Chair
2006-present, American Society of Clinical Oncology
Dr. Pal entered college at the age of 13 and began medical school at University of California Los Angeles at the age of 17. After completing his residency training at UCLA, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he has remained on faculty since 2009.
Over that span of time, he has published more than 300 PubMed cited articles that have been featured in prominent journals including Cancer Discovery, The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell and European Urology.
Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the West Coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at the Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets. He is the lead investigator on multiple trials, ranging from early phase 1 experiences to late stage phase 3 studies.
Dr. Pal sits on the editorial board for Kidney Cancer and is a reviewer for multiple journals including Lancet Oncology, The Journal of Clinical Oncology, The Journal of Urology, European Urology and many others. Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network and multiple other leading entities in support of his formidable research.
Clinical Teams
Bladder Cancer
Kidney and Renal Cancer
Medical Oncology & Therapeutics Research
Prostate Cancer
Testicular Cancer
Urology and Urologic Cancers Program
Awards
2020, 40 Under 40 in Cancer
2020, Los Angeles Business Journal, Top Doctor
Memberships
2006-present, American Society of Clinical Oncology
2017-present, Cancer Communications Committee, Chair
2016-present, Leadership Development Program
2015-present, Social Media Working Group
2013-present, Genitourinary Cancers Committee
2012-2013, HER2-Positive Breast Cancer Committee
2010-present, National Comprehensive Cancer Network Bladder Cancer Committee
2015-present, Kidney Cancer Association Scientific Program Committee, Chair
2015-present, Society of Immunotherapy for Cancer Patient Meeting, Chair
2015-present, Society of Urologic Oncology Prostate Cancer Committee, Chair
2006-present, American Society of Clinical Oncology
研究兴趣
论文共 721 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Hedyeh Ebrahimi, Sandra Megally,Elana Plotkin,Latha Shivakumar, Nicholas J Salgia,Zeynep B Zengin,Luis Meza,Neal Chawla, Daniella V Castro,Nazli Dizman, Ruma Bhagat, Seila Liv,
Renée Maria Saliby,Chris Labaki, Tejas R. Jammihal,Wanling Xie,Maxine Sun, Valisha Shah,Eddy Saad,M. Harry Kane,Soki Kashima, Katherine Sadak, Talal El Zarif, Deepak Poduval,
Cancer Cell (2024)
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meetingno. 2 (2024): e430428-e430428
Leonard J Appleman,Se Eun Kim,Wayne B Harris,Sumanta K Pal,Michael R Pins,Jill Kolesar,Neeraj Agarwal,Rahul A Parikh,Daniel A Vaena, Christopher W Ryan, Mehmood Hashmi,Brian A Costello,
Journal of clinical oncology : official journal of the American Society of Clinical Oncologypp.JCO2301544-JCO2301544, (2024)
ONCOLOGISTno. 3 (2024): 254-262
Journal of Clinical Oncologyno. 16_suppl (2024): 1038-1038
European Urology Focus (2024)
FRONTIERS IN IMMUNOLOGY (2024): 1274781-1274781
European Urology (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn